Pre-made Mirzotamab Clezutoclax benchmark antibody (Whole mAb ADC, anti-CD276 therapeutic antibody, Anti-4Ig-B7-H3/B7-H3/B7H3/B7RP-2 Antibody) for drug discovery and mechanism of action (MOA) research

Cat No.: GMP-Bios-INN-915

Pre-made Mirzotamab Clezutoclax benchmark antibody (Whole mAb ADC, anti-CD276 therapeutic antibody, Anti-4Ig-B7-H3/B7-H3/B7H3/B7RP-2 Antibody) is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.



Order information


* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry

Catalog No. Package Price(In USD) Qty (Quantity) Sum(In USD)
GMP-Bios-INN-915-1mg 1mg Inquiry
GMP-Bios-INN-915-10mg 10mg Inquiry
GMP-Bios-INN-915-100mg 100mg Inquiry
GMP-Bios-INN-915-xmg ≥100mg Inquiry
Shipping Cost: 760.00
Total:

For more than 100mg, click here for inquiry. >>


Description

Products Name (INN Index) Pre-Made Mirzotamab Clezutoclax Biosimilar, Whole Mab Adc, Anti-Cd276 Antibody: Anti-4Ig-B7-H3/B7-H3/B7H3/B7RP-2 therapeutic antibody Drug Conjugate
INN Name Mirzotamab Clezutoclax
TargetCD276
FormatWhole mAb ADC
DerivationChimeric Humanized
Species Reactivityhuman
CH1 IsotypeIgG1 - kappa
VD LCIgG1 - kappa
Highest_Clin_Trial (Jan '20)
Est. Status
100% SI Structure
99% SI Structure
95-98% SI Structure
Year Proposed
Year Recommended
CompaniesAbbVie Inc. (North Chicago IL USA)
Conditions Approved
Conditions Active
Conditions Discontinued
Development Tech0